Drug intelligence / Profile preview

mitoxantrone + vinblastine

Development stage: Preclinical
Lead developer: National Cancer Institute
Modality: Small Molecules
Administration: Intravenous

Overview

A chemotherapy combination regimen consisting of mitoxantrone, a DNA-reactive agent that intercalates into DNA causing crosslinks and strand breaks while inhibiting topoisomerase II, and vinblastine, which is typically administered as a continuous intravenous infusion. This combination has been studied for treating metastatic breast cancer and canine urothelial cell carcinoma (bladder cancer).

Targets

TOP2B (DNA topoisomerase II beta)PIM1 (Proviral integration site for moloney murine leukemia virus kinase 1)TUBB (Tubulin (alpha and beta subunits))TOP2A (DNA topoisomerase II)DNA

Beyond the preview

Go deeper on mitoxantrone + vinblastine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mitoxantrone + vinblastine.

Explore the full profile